Literature DB >> 19712646

Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?

E van Nood1, P Speelman, E J Kuijper, J J Keller.   

Abstract

Patients with recurrent Clostridium difficile infections (CDI) in hospitals and the community constitute an increasing treatment problem. While most patients with a first infection respond to either metronidazole or oral vancomycin, therapy in recurrent C. difficile infections tends to fail repeatedly. Lack of alternative treatment options can be a tremendous burden, both to patients and their treating physicians. Most guidelines recommend prolonged oral vancomycin pulse and or tapering schedules, but evidence-based treatment strategies are lacking. The role of immunoglobulins, whey prepared from vaccinated cows, probiotics or other antibiotics is unclear. Since 1958 several case series and case reports describe a treatment strategy where faecal infusions are successfully given for the treatment of recurrent CDI. Restoring intestinal flora has been historically thought of as the mechanism responsible for cure in these patients. In the literature, more than 150 patients have received faeces from a healthy donor, either infused through an enema, or through a nasoduodenal or nasogastric tube. We summarise the literature regarding treatment with donor faeces for recurrent CDI, and introduce the FECAL trial, currently open for inclusion.

Entities:  

Mesh:

Year:  2009        PMID: 19712646     DOI: 10.2807/ese.14.34.19316-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  29 in total

Review 1.  The human microbiome and its potential importance to pediatrics.

Authors:  Coreen L Johnson; James Versalovic
Journal:  Pediatrics       Date:  2012-04-02       Impact factor: 7.124

Review 2.  Microbiota restoration: natural and supplemented recovery of human microbial communities.

Authors:  Gregor Reid; Jessica A Younes; Henny C Van der Mei; Gregory B Gloor; Rob Knight; Henk J Busscher
Journal:  Nat Rev Microbiol       Date:  2010-11-29       Impact factor: 60.633

Review 3.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

4.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

5.  The art of targeting gut microbiota for tackling human obesity.

Authors:  Marisol Aguirre; Koen Venema
Journal:  Genes Nutr       Date:  2015-05-20       Impact factor: 5.523

Review 6.  A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics.

Authors:  Emma Allen-Vercoe; Gregor Reid; Norman Viner; Gregory B Gloor; Susy Hota; Peter Kim; Christine Lee; Kieran O'Doherty; Stephen J Vanner; J Scott Weese; Elaine O Petrof
Journal:  Can J Gastroenterol       Date:  2012-07       Impact factor: 3.522

Review 7.  Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.

Authors:  Ryan Eliott; Pratik Panchal; Shrish Budree; Alex Scheeler; Geraldine Medina; Monica Seng; Wing Fei Wong; Thomas Mitchell; Zain Kassam; Jessica R Allegretti; Majdi Osman
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 8.  Fecal microbiota transplantation and emerging applications.

Authors:  Thomas J Borody; Alexander Khoruts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-12-20       Impact factor: 46.802

9.  Fecal microbiota transplantation in relapsing Clostridium difficile infection.

Authors:  Faith Rohlke; Neil Stollman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 10.  Fecal microbiota transplantation for management of Clostridium difficile infection.

Authors:  Chetana Vaishnavi
Journal:  Indian J Gastroenterol       Date:  2014-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.